	June 30, 2020		December 31, 2019
Accrued legal verdict expense	$	31,536	$	31,350
Accrued royalties		8,091		8,866
Accrued CRO services		4,273		8,502
Accrued variable consideration		11,096		7,978
Accrued bonus		4,053		1,618
Accrued compensation		5,342		4,138
Accrued other clinical development		1,225		2,546
Accrued professional fees		1,343		1,775
Accrued legal fees		652		266
Accrued manufacturing costs		675		869
Other		354		1,122
Totals	$	68,640	$	69,030

Accrued CRO services, accrued other clinical development expenses, and accrued legal fees represent the Company’s estimates of such costs and are recognized as incurred. Accrued royalties represent royalties incurred in connection with the Company’s license agreement with Pfizer. Accrued compensation includes accrued commissions and accrued vacation, which is accrued at the rate the employee earns vacation and reduced as vacation is used by the employee. Accrued variable consideration represents estimates of adjustments to product revenue, net for which reserves are established. Other accrued expenses consist primarily of accrued contractor/consultant costs, business license fees, taxes, insurance, and marketing fees.

Accrued legal verdict expense represents an estimate of a range between $9.1 million and $18.1 million that may be owed to class action participants as a result of the jury verdict in Hsu v. Puma Biotechnology, Inc., and an estimate of $22.4 million that may be owed to the plaintiff as a result of the jury verdict in Eshelman v. Puma Biotechnology, Inc., et al. The total amount of damages in Hsu and Eshelman is uncertain and will be ascertained only after an extensive claims process in Hsu, and the completion of post-trial proceedings, and the exhaustion of any appeals in both cases. It is also reasonably possible that the total damages will be higher than these estimates.